BridgeBio · 1 week ago
Executive Director, U.S. Public Policy (CMS, HHS & Payment Policy)
Washington, DC
Full-time
Hybrid
Director/Executive
$305K/yr - $350K/yr
15+ years expBridgeBio is a pioneering company in the biotech sector focused on developing life-changing medicines for patients with unmet needs. The Executive Director, U.S. Public Policy will lead the public policy strategy related to Medicare, Medicaid, and payment models, advising executive leadership and shaping policy positions that influence access and reimbursement.
BiotechnologyHealth CareLife ScienceMedicalPharmaceutical
Responsibilities
Define and lead BridgeBio’s U.S. public policy strategy, particularly Medicare (Parts B and D), Medicaid, alternative and value-based payment models, IRA implementation, CMMI initiatives, and coverage and reimbursement policy
Serve as the company’s internal expert on U.S. public policy, advising leadership on policy design, implementation risk, and long-term implications
Translate complex public policy developments into clear strategic options and recommendations for executive leadership
Act as BridgeBio’s primary interface with CMS and HHS, engaging directly with agency leadership, career staff, and relevant HHS offices
Bring and leverage an extensive existing network across CMS and HHS to inform strategy and anticipate policy direction
Represent BridgeBio externally in public policy coalitions, trade associations, and forums where coverage, payment, and access policy are central
Apply strong analytical and modeling skills to assess financial, access, and portfolio-level impacts of U.S. public policy proposals and payment models
Partner closely with Strategic Finance, Commercial, Market Access, and Government Affairs teams to model implications of Medicare and Medicaid policy changes, reimbursement dynamics, and payment reform initiatives
Develop rigorous, data-driven policy analyses to support advocacy positions and executive decision-making
Work collaboratively with Commercial, Government Affairs, Market Access, Strategic Finance, Medical, and Patient Advocacy teams to ensure public policy strategy is fully integrated across the organization
Serve as a trusted advisor to executive leadership on U.S. public policy matters
Prepare executive level briefings, scenario analyses, and policy updates
Qualification
Required
15+ years of experience in U.S. health policy
Graduate-level degree required (MPH, MPP, JD, PhD, MBA)
Prior CMS experience, payor, and/or top-tier management consulting experience with deep CMS and HHS exposure strongly preferred
Extensive expertise in Medicare, Medicaid, and U.S. payment models
Recognized public policy expert with demonstrated experience engaging CMS and HHS as regulators
Extensive professional network across CMS and HHS
Strong analytical, quantitative, and policy modeling capabilities
Proven ability to operate independently and lead public policy strategy in a complex organization
Preferred
Prior CMS experience, payor, and/or top-tier management consulting experience with deep CMS and HHS exposure strongly preferred
Benefits
401K with 100% employer match on first 3% & 50% on the next 2%
Employee stock purchase program
Pre-tax commuter benefits
Referral program with $2,500 award for hired referrals
Comprehensive health care with 100% premiums covered - no cost to you and dependents
Mental health support via Spring Health (6 therapy sessions & 6 coaching sessions)
Hybrid work model - employees have the autonomy in where and how they do their work
Unlimited flexible paid time off - take the time that you need
Paid parental leave - 4 months for birthing parents & 2 months for non-birthing parents
Flex spending accounts & company-provided group term life & disability
Subsidized lunch via Forkable on days worked from our office
Career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, Spring Health & BetterUp Coaching
Financial rewards, peer-to-peer recognition, and growth opportunities
Company
BridgeBio
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
201-500 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.9BKey Investors
Blue OwlQatar Investment AuthorityKohlberg Kravis Roberts
2026-01-16Debt Financing· $550M
2025-02-25Post Ipo Debt· $500M
2024-03-04Post Ipo Equity· $250M
Leadership Team
Justin To
CEO, Skeletal Dysplasias (QED Therapeutics)
Neil Kumar
CEO and Founder
Recent News
BioWorld Financial Watch
2026-01-17
Company data provided by crunchbase